Belite Bio Soars on Breakthrough Stargardt Disease Trial Results

Belite Bio shares are trading higher after the company announced positive topline results from its pivotal Phase 3 DRAGON trial of Tinlarebant, marking a historic breakthrough for Stargardt disease treatment.